Comparison
Ipamorelin vs. Matrixyl
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Cosmetic
CAS no.
170851-70-4
214047-00-4
Molecular weight
711.86 g/mol
802.06 g/mol
Half-life
2 h
no data
Sequence
Aib-His-D-2-Nal-D-Phe-Lys-NH2Palmitoyl-Lys-Thr-Thr-Lys-SerMechanism of action
Ipamorelin
Ipamorelin is a selective agonist at the GH secretagogue receptor (GHSR-1a). Compared to GHRP-2 and GHRP-6 its selectivity for the growth-hormone axis is higher; ACTH, cortisol and prolactin are not significantly stimulated in clinical studies. This selectivity was the main reason for its development over older GHRPs.
Matrixyl
KTTKS is a fragment of the procollagen I sequence and appears to be part of a feedback mechanism in fibroblasts: elevated concentrations signal intact collagen synthesis and downregulate new synthesis, while low concentrations stimulate it. In cell-culture studies, stimulation of collagen types I/III, elastin, fibronectin and glycosaminoglycans has been documented. The palmitoyl modification is intended to improve skin penetration; effect at the site of action (dermal fibroblasts) depends on permeation.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
4
5
of which in humans
3
2
Effects recorded
3
3
Open conflicts
1
0
Documented adverse events
1
1